Today, Seattle-based Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases announced the FDA has issued a “Safe to Proceed” letter under their Expanded Access Pathway, permitting the use of Atossa’s oral Endoxifen as a treatment in an ovarian cancer patient. The patient is being treated at the University of Washington Medical Center by Dr. Barbara Goff, Surgeon-in-Chief. Under the FDA expanded access program, the use of Atossa’s proprietary oral Endoxifen is restricted solely to this patient. Approval from the Institutional Review Board (IRB) must be obtained prior to providing oral Endoxifen to this patient.
“Dr. Goff recently contacted Atossa with an interest in gaining access to our Endoxifen under the FDA’s expanded access, or compassionate use, program for one of her patients. The patient has recurrent ovarian cancer and recently underwent functional molecular genomic testing, using 3D tumor organoid cultures grown in the laboratory from the patient’s tumor. The organoid testing revealed that the combination of Endoxifen and alpelisib produced an exceptional tumor response. We are gratified to be able to help this patient and are anxious to follow her response to this drug combination. If the drug combination shows promise in this patient, Atossa will consider doing additional clinical studies in patients with ovarian cancer” stated, Steven Quay, M.D., Ph.D., Atossa’s President and CEO.
ABOUT ATOSSA’S PROPRIETARY ENDOXIFEN
Endoxifen is an active metabolite of tamoxifen, which is an FDA-approved drug to treat ovarian and breast cancer. Tamoxifen itself must be broken down by the liver into active compounds (metabolites), of which Endoxifen is the most active. In third party preclinical studies, endocrine-sensitive and letrozole-resistant breast tumors, Z-endoxifen resulted in robust antitumor and antiestrogenic activity compared to tamoxifen and aromatase inhibitor monotherapy.
Atossa has been developing its proprietary oral Endoxifen for breast cancer and other breast conditions and has successfully completed five clinical studies with this drug, including an expanded access study of a female breast cancer patient who has been taking oral Endoxifen for over two years, with no recurrence to date.
Alpelisib was approved in the United States in 2019 for use in combination with the endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. PIK3 is a family of lipid kinases and one of them, PIK3CA, has mutations or gene amplification detected in 30.5% of all ovarian cancers and 45% of the endometrioid and clear cell subtypes. Alpelisib is marketed by Novartis under the brand name of Piqray.
Please condor visiting the Atossa Therapeutics (NASDAQ: ATOS) page within the VP Watchlist pages at our site to learn more and to stay up today on their progress.